Alembic settles patent dispute with Novartis

Vadodara-based pharmaceuticals products maker, Ltd (APL) along with a US-based Breckenridge Pharmaceutical Inc, has settled a patent dispute with regarding Rivastigmine Tartrate Capsules, a generic version of Exelon.

In a statement filed with the Bombay Stock Exchange (BSE), Alembic stated that the company and Breckenridge have settled their paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon by Novartis.

Alembic has also received the US Food and Drug Administration (USFDA) approval for their Abbreviated New Drug Application (ANDA).

"The will launch product immediately. Under the terms of the settlement agreement, Novartis has granted Breckenridge and Alembic a license to market a generic version of Exelon before the expiration of US Patent on February 11, 2014," the company statement said on Friday.

Alembic would make the drug, while Breckenridge would market it exclusively in the US.

The product will be available in four strengths, 1.5 mg, 3 mg, 4.5 mg and 6 mg, the company stated.

is a prescription medicine that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia of associated with Parkinson's disease. Alembic shares surged on post the announcement on Friday. The company shares traded positive, up by nearly 5 per cent at Rs 53.90 during trading hours.

image
Business Standard
177 22
Business Standard

Alembic settles patent dispute with Novartis

BS Reporter  |  Mumbai/ Ahmedabad 



Vadodara-based pharmaceuticals products maker, Ltd (APL) along with a US-based Breckenridge Pharmaceutical Inc, has settled a patent dispute with regarding Rivastigmine Tartrate Capsules, a generic version of Exelon.

In a statement filed with the Bombay Stock Exchange (BSE), Alembic stated that the company and Breckenridge have settled their paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon by Novartis.

Alembic has also received the US Food and Drug Administration (USFDA) approval for their Abbreviated New Drug Application (ANDA).

"The will launch product immediately. Under the terms of the settlement agreement, Novartis has granted Breckenridge and Alembic a license to market a generic version of Exelon before the expiration of US Patent on February 11, 2014," the company statement said on Friday.

Alembic would make the drug, while Breckenridge would market it exclusively in the US.

The product will be available in four strengths, 1.5 mg, 3 mg, 4.5 mg and 6 mg, the company stated.

is a prescription medicine that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia of associated with Parkinson's disease. Alembic shares surged on post the announcement on Friday. The company shares traded positive, up by nearly 5 per cent at Rs 53.90 during trading hours.

RECOMMENDED FOR YOU

Alembic settles patent dispute with Novartis

Vadodara-based pharmaceuticals products maker, Alembic Pharmaceuticals Ltd (APL) along with a US-based Breckenridge Pharmaceutical Inc, has settled a patent dispute with Novartis AG regarding Rivastigmine Tartrate Capsules, a generic version of Exelon.

Vadodara-based pharmaceuticals products maker, Ltd (APL) along with a US-based Breckenridge Pharmaceutical Inc, has settled a patent dispute with regarding Rivastigmine Tartrate Capsules, a generic version of Exelon.

In a statement filed with the Bombay Stock Exchange (BSE), Alembic stated that the company and Breckenridge have settled their paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon by Novartis.

Alembic has also received the US Food and Drug Administration (USFDA) approval for their Abbreviated New Drug Application (ANDA).

"The will launch product immediately. Under the terms of the settlement agreement, Novartis has granted Breckenridge and Alembic a license to market a generic version of Exelon before the expiration of US Patent on February 11, 2014," the company statement said on Friday.

Alembic would make the drug, while Breckenridge would market it exclusively in the US.

The product will be available in four strengths, 1.5 mg, 3 mg, 4.5 mg and 6 mg, the company stated.

is a prescription medicine that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia of associated with Parkinson's disease. Alembic shares surged on post the announcement on Friday. The company shares traded positive, up by nearly 5 per cent at Rs 53.90 during trading hours.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard